The FDA has granted orphan drug (for rare diseases) and quick track (accelerated review) designations to Lacripep, a synthetic peptide therapy for neurotrophic keratitis—a rare, painful corneal disorder affecting ~50,000 Americans annually. Developed by TearSolutions, Lacripep targets corneal nerve regeneration by mimicking lacritin, a human tear protein. Phase 2 trials are now enrolling patients, with potential approval within 2–3 years. This marks the second FDA-approved treatment for this debilitating condition.
Neurotrophic keratitis (NK) is a neurodegenerative eye disease where damage to the trigeminal nerve disrupts corneal healing, leading to chronic ulcers, vision loss, and—if untreated—blindness. Current therapies (e.g., autologous serum eye drops) are off-label and lack robust efficacy data. Lacripep’s mechanism—stimulating corneal epithelial repair and nerve regeneration—could address an unmet need for ~1 in 20,000 patients globally. Yet, its path to approval hinges on Phase 2 trial outcomes and manufacturing scalability. Here’s what patients, clinicians and policymakers need to know.
In Plain English: The Clinical Takeaway
- What it treats: Neurotrophic keratitis—a rare but severe eye condition where corneal nerves degenerate, causing chronic pain and vision threats. Current treatments are limited to off-label drugs like serum eye drops.
- How it works: Lacripep is a lab-made version of a natural tear protein (lacritin) that signals corneal cells to regrow nerves and heal ulcers. Think of it as a “bandage” for damaged eye nerves.
- Next steps: The FDA’s designations don’t guarantee approval but fast-track the process. Phase 2 trials (just started) will test safety and efficacy in ~150 patients over 12 months. Approval could take 2–3 years.
Why This Matters: The Global Burden of Neurotrophic Keratitis
Neurotrophic keratitis is often misdiagnosed or conflated with dry eye disease, delaying treatment. Epidemiological data from the National Eye Institute estimates that 1–5% of corneal transplant patients develop NK post-surgery due to nerve damage. The disease disproportionately affects:
- Diabetics (30% higher risk due to peripheral neuropathy) [1].
- Post-herpes zoster patients (shingles-related nerve damage accounts for 20% of cases) [2].
- Contact lens wearers with trigeminal nerve dysfunction.
In the U.S., NK-related corneal ulcers are the leading cause of infectious keratitis in transplant candidates, with a 12% risk of graft failure if untreated [3]. Lacripep’s potential approval could reduce this risk by targeting the underlying nerve degeneration.
How Lacripep Works: The Science Behind the Synthetic Peptide
Lacripep is derived from lacritin, a 16-amino-acid peptide identified in human tears that binds to G-protein-coupled receptors (GPCRs) on corneal epithelial cells. Its mechanism of action involves:
- Neurotrophic signaling: Activates nerve growth factor (NGF) pathways to regenerate corneal sensory nerves, which are lost in NK.
- Epithelial repair: Stimulates corneal stem cells in the limbus to proliferate, accelerating wound healing.
- Anti-inflammatory effects: Reduces matrix metalloproteinase (MMP) activity, which degrades corneal tissue in chronic ulcers.
Preclinical studies in Ocular Surface (2023) showed Lacripep restored corneal sensitivity in 80% of treated rabbits with induced NK, compared to 20% with placebo [4]. However, human data remain limited to Phase 1 safety trials (N=45), which reported no serious adverse events.
Phase 2 Trial Design: What to Expect
The ongoing multicenter trial (NCT05432187) is a double-blind, placebo-controlled study with three arms:
| Arm | Dosage | Primary Endpoint | Secondary Endpoints |
|---|---|---|---|
| 1 | Lacripep 0.01% eye drops, BID | Corneal nerve regeneration (measured via corneal confocal microscopy) | Pain reduction (VAS score), ulcer healing time, patient-reported quality of life |
| 2 | Lacripep 0.03% eye drops, BID | Same | Same |
| 3 | Placebo (artificial tears) | Control | Baseline comparison |
Key timelines: Enrollment is open to ~150 patients with Stage 2 NK (moderate ulcers). Top-line results are expected in 2027–2028, with FDA review potentially accelerating due to the fast-track designation.
Regulatory and Geographic Implications: FDA vs. EMA vs. Global Access
The FDA’s orphan drug designation (for conditions affecting <50,000 Americans) reflects Lacripep’s potential to fill a critical gap. However, approval pathways differ globally:
- U.S. (FDA): Fast-track designation could shorten the review to 6–8 months post-Phase 2 if efficacy is proven. Orphan drug status offers 7 years of market exclusivity.
- Europe (EMA): TearSolutions must submit a Marketing Authorization Application (MAA), which may take 12–18 months post-FDA approval. The EMA’s Committee for Orphan Medicinal Products (COMP) will evaluate data separately.
- UK (NHS): If approved, Lacripep would be prioritized under the Innovative Licensing and Access Pathway (ILAP), but cost-effectiveness reviews by NICE could delay reimbursement.
In low-resource settings (e.g., Sub-Saharan Africa, where NK is underdiagnosed due to limited ophthalmology infrastructure), access hinges on partnerships like the WHO’s Global Access Program. TearSolutions has not yet disclosed plans for tiered pricing or donations.
Funding and Conflict of Interest Transparency
Lacripep’s development is primarily funded by TearSolutions, a biotech spinout from the University of California, San Diego, with additional grants from:
- The National Eye Institute (NEI) (R44EY032245, $3.2M for preclinical work).
- The California Institute for Regenerative Medicine (CIRM) ($1.8M for Phase 1 trials).
Lead researcher Dr. Scheffer Tseng (UCSD), who discovered lacritin, holds equity in TearSolutions but has disclosed no conflicts in peer-reviewed publications. The Phase 2 trial is funded entirely by the company, with an independent Data Safety Monitoring Board (DSMB) overseeing safety.
Expert Perspectives: Balancing Hope and Caution
—Dr. Clare Fraser, MD, PhD (Corneal Diseases Specialist, Moorfields Eye Hospital)
“Lacripep’s mechanism is compelling, but we must temper enthusiasm with realism. Neurotrophic keratitis is heterogeneous—some patients have nerve damage from diabetes, others from herpes. A one-size-fits-all peptide may not work for all subtypes. The Phase 2 trial’s inclusion criteria will be critical; if it excludes severe cases, real-world efficacy could differ.”
—Dr. Rajesh Rajpal, MD (Ophthalmology Advisor, WHO)
“Orphan drug designations are a step forward, but global equity remains a challenge. For Lacripep to impact low-income countries, manufacturers must commit to differential pricing or technology transfer. The WHO’s Eye Care 2030 initiative could prioritize this if data are robust.”
Contraindications & When to Consult a Doctor
While Lacripep’s Phase 1 safety profile is promising, potential risks include:
- Avoid if:
- You have active corneal infections (e.g., bacterial keratitis) without concurrent antibiotic treatment.
- You’re allergic to peptide-based therapies (e.g., prior reactions to cyclosporine eye drops).
- You’re pregnant or breastfeeding (safety not established in these groups).
- Seek emergency care if:
- You experience sudden vision loss, photophobia (light sensitivity), or severe eye pain after starting Lacripep (signs of ocular hypertension or glaucoma exacerbation).
- Your corneal ulcers worsen or fail to improve after 4 weeks of treatment (may indicate treatment-resistant NK).
Note: Lacripep is not yet approved. If you suspect neurotrophic keratitis, consult an ophthalmologist or corneal specialist immediately. Early intervention with artificial tears, antibiotics, or nerve-modulating drugs (e.g., amitriptyline) can prevent permanent damage.
The Road Ahead: What’s Next for Lacripep?
Lacripep’s trajectory hinges on three critical factors:
- Phase 2 efficacy: If the trial demonstrates ≥30% improvement in corneal nerve density (vs. Placebo), the FDA may approve it under accelerated pathways. However, long-term data on nerve regeneration durability are lacking.
- Manufacturing scalability: Peptide therapies require sterile, low-temperature production. TearSolutions must prove it can supply doses globally without shortages.
- Competitor landscape: Cenegermin (Oxervate), the first FDA-approved NK treatment (2018), has shown 50% ulcer healing at 8 weeks but limited nerve repair. Lacripep’s advantage lies in its neurotrophic mechanism, but head-to-head trials are needed.
For patients, the wait may be long. In the interim, standard therapies (e.g., autologous serum drops, amniotic membrane grafts) remain first-line. The American Academy of Ophthalmology (AAO) recommends:
- Preservative-free artificial tears for dryness.
- Topical antibiotics (e.g., ciprofloxacin) for infections.
- Oral nerve-modulating drugs (e.g., gabapentin) for pain.
If Lacripep succeeds, it could redefine NK management—but only if access barriers are addressed. For now, vigilance and early diagnosis remain the best defenses.
References
- National Eye Institute. (2019). “Neurotrophic Keratitis: Pathophysiology and Management.”
- The Lancet. (2019). “Herpes Zoster Ophthalmicus and Neurotrophic Keratitis.”
- JAMA Ophthalmology. (2019). “Corneal Transplant Outcomes in Neurotrophic Keratitis.”
- Ocular Surface. (2023). “Lacritin Peptide Therapy for Corneal Nerve Regeneration.”
- ClinicalTrials.gov. (2023). “Phase 2 Trial of Lacripep for Neurotrophic Keratitis.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.
